Danish pharmaceutical company Novo Nordisk is far too cheap. This is according to SEB's equity strategist Esbjörn Lundevall in an interview with Di TV.

He believes that the share is worth buying after the collapse of recent months.

"It's about p/e 17 for next year, for a company whose profits are growing around 25 percent a year," says Esbjörn Lundevall.